Kiniksa Pharmaceuticals International, plcKNSA
時価総額
$61.5億
PER
希少疾患向けバイオ医薬品の新興企業。ARCALYSTやvixarelimab、KPL-387などの候補薬を展開。2016年9月に外部企業からvixarelimab関連資産を買収し11,500千ドル支払い。米国・欧州・中国で展開。
| 2018年 12月31日 | 2019年 12月31日 | 2020年 12月31日 | 2021年 12月31日 | 2022年 12月31日 | 2023年 12月31日 | 2024年 12月31日 | |
| Product | - | - | - | - | 123 | 233 | 417 |
| Collaboration | - | - | - | - | 98 | 37 | 6 |
| Revenue | - | - | - | 39 | 220 | 270 | 423 |
| Product | - | - | - | - | 23 | 33 | - |
| Collaboration | - | - | - | - | 24 | 57 | - |
| Cost of goods sold | - | - | - | 9 | - | - | 61 |
| Collaboration expenses | - | - | - | - | - | - | 128 |
| Research and development | 87 | 135 | 112 | 99 | 65 | 76 | 112 |
| Selling, general and administrative | - | - | - | 86 | 98 | 129 | 168 |
| Total operating expenses | - | - | - | 195 | 210 | 295 | 469 |
| Income (loss) from operations | -108 | -170 | -157 | -157 | 10 | -25 | -46 |
| Other income | - | - | - | - | 1 | 9 | 9 |
| Income (loss) before income taxes | -103 | -164 | -156 | -157 | 11 | -17 | -36 |
| Benefit (provision) for income taxes | -0 | -2 | 5 | 1 | -172 | -31 | 7 |
| Net income (loss) | -103 | -162 | -161 | -158 | 183 | 14 | -43 |
| Earnings Per Share, Basic | - | - | - | -2.3 | 2.64 | 0.2 | -0.6 |
| Earnings Per Share, Diluted | - | - | - | -2.3 | 2.6 | 0.2 | -0.6 |
| Net income (loss) | -103 | -162 | -161 | -158 | 183 | 14 | -43 |
| Unrealized gain (loss) on short-term investments and currency translation adjustments, net of tax | -0 | 0 | -0 | -0 | 0 | -0 | -0 |
| Total other comprehensive income (loss) | -0 | 0 | -0 | -0 | 0 | -0 | -0 |
| Total comprehensive income (loss) | -103 | -162 | -161 | -158 | 183 | 14 | -43 |